Sign In
Buy SUPN
$44.04
-0.0350 (-0.0794%)
At Close: Jun 03, 2026
Supernus Pharmaceuticals (SUPN) Q2 Earnings Lag Estimates
06:48pm, Thursday, 04'th Aug 2022
Supernus (SUPN) delivered earnings and revenue surprises of -53.33% and 2.23%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
09:00pm, Monday, 25'th Jul 2022 GlobeNewswire Inc.
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals to Announce Second Quarter 2022 Financial Results and Host Conference Call on August 4, 2022
05:00pm, Monday, 25'th Jul 2022
ROCKVILLE, Md., July 25, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cen
2 Small-Cap Stocks With Large-Cap Potential
03:45pm, Monday, 11'th Jul 2022 The Motley Fool
They're already raking in revenue, and more is on the way.
Supernus to Participate in the Jefferies Healthcare Conference
08:05pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
ROCKVILLE, Md., June 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of c
Supernus Pharmaceuticals, Inc. (SUPN) CEO Jack Khattar on Q1 2022 Results - Earnings Call Transcript
08:24pm, Monday, 09'th May 2022
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN ) Q1 2022 Earnings Conference Call May 9, 2022 4:30 PM ET Company Participants Peter Vozzo - Westwicke, Investor Relations Jack Khattar - Chief Executive Of
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
08:55pm, Monday, 02'nd May 2022 GlobeNewswire Inc.
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of ce
Supernus Pharmaceuticals to Announce First Quarter 2022 Financial Results and Host Conference Call on May 9, 2022
04:55pm, Monday, 02'nd May 2022
ROCKVILLE, Md., May 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of cent
Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults
12:00am, Saturday, 30'th Apr 2022 GlobeNewswire Inc.
ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of
Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
08:11pm, Wednesday, 13'th Apr 2022 GlobeNewswire Inc.
ROCKVILLE, Md., April 13, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of
Supernus Provides Update on Filing of Annual Report and Reiterates Full Year 2022 Financial Guidance
09:00pm, Monday, 04'th Apr 2022 GlobeNewswire Inc.
ROCKVILLE, Md., April 04, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of
Attention Biotech Investors: Mark Your Calendar For April PDUFA Dates
07:16pm, Friday, 01'st Apr 2022 Benzinga
Biopharma stocks are sensitive to a key binary event called the PDUFA date, the date by which the Food and Drug Administration is required to give its verdict on a regulatory application filed with it
Supernus Notifies Nasdaq Regarding Non-Compliance with Listing Requirement and Expectation to Regain Compliance
12:30pm, Thursday, 17'th Mar 2022 GlobeNewswire Inc.
ROCKVILLE, Md., March 17, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of
Supernus to Participate in Annual Cowen Health Care Conference
01:00pm, Wednesday, 02'nd Mar 2022 GlobeNewswire Inc.
ROCKVILLE, Md., March 02, 2022 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of
